Tetratherix Limited (ASX:TTX)
Australia · Delayed Price · Currency is AUD 7.31
+0.13 (1.81%)
Sep 9, 2026, 4:10 PM AEST
Tetratherix Revenue
In the fiscal year ending June 30, 2026, Tetratherix had annual revenue of 3.86M AUD with 266.87% growth. Tetratherix had revenue of 2.46M in the half year ending June 30, 2026, with 673.22% growth.
Revenue
3.86M
Revenue Growth
+266.87%
P/S Ratio
100.39
Revenue / Employee
154.47K
Employees
25
Market Cap
387.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.86M | 2.81M | 266.87% |
| Jun 30, 2025 | 1.05M | 188.97K | 21.88% |
| Jun 30, 2024 | 863.65K | 297.37K | 52.51% |
| Jun 30, 2023 | 566.28K | -541.55K | -48.88% |
| Jun 30, 2022 | 1.11M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 94.02M |
| BLS Pharmaceuticals | 73.91M |
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Orthocell | 11.41M |
| Clarity Pharmaceuticals | 10.53M |
| Dimerix | 6.35M |
| Racura Oncology | 2.81M |